Papua New Guinea
Tuberculosis profile
Population  2013 7.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.4 (0.62–5.5) 33 (8.5–75)
Mortality (HIV+TB only) 0.39 (0.18–0.68) 5.4 (2.5–9.3)
Prevalence  (includes HIV+TB) 32 (14–57) 437 (195–775)
Incidence  (includes HIV+TB) 25 (20–32) 347 (269–437)
Incidence (HIV+TB only) 2.3 (0.85–2.9) 32 (12–40)
Case detection, all forms (%) 89 (71–110)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.7–6.4) 24 (20–27)
MDR-TB cases among notified pulmonary
TB cases
560 (340–800) 570 (480–650)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 150   198
Pulmonary, clinically diagnosed 9 390    
Extrapulmonary 9 919    
       
Total new and relapse 22 657    
Previously treated, excluding relapses 2 203    
Total cases notified 24 860    
Among 22 399 new cases:
6 325 (28%) cases aged under 15 years;
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB     2 143
Laboratory-confirmed RR-/MDR-TB cases     129
Patients started on MDR-TB treatment     145
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 939 (24)
HIV-positive TB patients 807 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 187 (23)
HIV-positive TB patients on antiretroviral therapy (ART) 307 (38)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 68
Previously treated cases registered in 2012 56
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 14
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 12
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 14
% Funded domestically 44%
% Funded internationally 26%
% Unfunded 30%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-30 Data: www.who.int/tb/data